EU CAR T: Expert Perspective
Secondary malignancies after Car T-cell therapy
Dr Anna Sureda
Clinical Hematology Department, Institut Català d 'Oncologia L'Hospitalet, Barcelona, Spain
Dr Anna Sureda of Institut Català d'Oncologia, Barcelona, Spain, gives her perspective regarding the risk of secondary malignancies after CAR-T cell therapy and how clinicians should view this when considering CAR T as a treatment option with curative potential for their patients